Danaher Q2 Earnings Surge 60% on Masimo Boost; Debt Load Doubles

summarizeSummary

Danaher reported Q2 2026 net earnings of $870 million, up 60% year-over-year, as the $9.8 billion Masimo acquisition closed and core sales grew 3%. Total debt more than doubled to $26.6 billion to fund the deal.

check_boxKey Events · Earnings and Guidance · DHR

• Q2 Earnings Surge 60%

  Net earnings reached $870 million, or $1.23 per diluted share, compared to $555 million a year ago. The prior-year quarter included a $432 million impairment charge.

• Masimo Acquisition Closed

  Danaher completed the $9.8 billion acquisition of Masimo on June 10, adding patient monitoring technologies to its Diagnostics segment. The deal contributed $4.96 billion in goodwill and $4.84 billion in intangible assets.

• Debt Load Doubles to $26.6B

  Total debt increased to $26.6 billion from $18.4 billion at year-end 2025, primarily to fund the Masimo acquisition. A new $5 billion 364-day credit facility was established in April 2026.

• Core Sales Growth of 3%

  Core sales grew 3.0% in Q2, or 4.5% excluding respiratory testing. Life Sciences led with 5.5% core growth, while Biotechnology grew 2.5% and Diagnostics 2.0%.

auto_awesomeAnalysis · DHR · Industrial Applications And Services

Second-quarter net earnings jumped 60% to $870 million, propelled by the June 10 closing of the $9.8 billion Masimo acquisition and solid core sales growth of 3%. The deal transforms the Diagnostics segment but comes at a cost: total debt ballooned to $26.6 billion from $18.4 billion at year-end, funded by a new $5 billion credit facility and multi-currency note offerings. Operating margins expanded sharply to 18% from 12.8% a year ago, though the prior-year period included a $432 million impairment charge. The company repurchased $903 million in shares during the quarter, signaling confidence, but the leverage increase and integration risks from Masimo — including a web of litigation — warrant close attention.